Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
ONCY
Primary Symbol:
T.ONC
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(216)
•••
13X2413
X
View Profile
View Bullboard History
Post by
13X2413
on Nov 04, 2024 10:34am
Another Fine Start To The Week
I know, I know. Stock price means nothing. Lots in the works. Companies dying to buy us out for gazillions. Be patient.
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 04, 2024 10:21am
RE:RE:RE:CAR-T update
Should read: The FDA is reconsidering removing serious safety warnings on CAR-T therapies
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 04, 2024 10:20am
RE:RE:CAR-T update
November 01, 2024 - The FDA is reconsidering reoving serious safety warnings on CAR-T therapies with plans to change them potentially, Peter Marks, M.D., Ph.D., director of the FDA’s Center for
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Comment by
canadafan
on Nov 03, 2024 10:05pm
RE:RE:RE:RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC
Very little has been said about the IRENE study. that was initiated alongside Incyte. adding to the ongoing relationship with Roche. imho, lots of excitement ahead.
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 03, 2024 9:21pm
RE:RE:RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC
"Prior clinical studies have shown that pelareorep upregulates tumor PD-L1 expression and reverses immunosuppressive TMEs,” said Mridula George, M.D., Medical Oncologist, Rutgers Cancer Institute
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 03, 2024 9:14pm
RE:RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC
" Background: Triple negative breast cancer (TNBC) is an aggressive subtype accounting for 15% of all breast cancer subtypes. It is characterized by larger tumor size, higher
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Nov 03, 2024 2:27pm
Though forward …??
So far, no update or nR regarding Q3 results usually out by now. could mean something of interest? Or just internal delays They do have until Nov29. My wish? they are in
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 03, 2024 9:36am
RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO
ONCY reported on TCR sequencing in the recent GOBLET Phase 1/2 clinical trial in metastatic pancreatic cancer. TCR sequencing is a technique that measures the diversity and clonality of T
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 03, 2024 9:33am
RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO
Repost from October 2023: Overall (TCR) TILS is a strong prognostic biomarker in an early stage setting. ONCYs GOBLET study further confirmed T cell diversity and TCR clonality as
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 02, 2024 11:38pm
RE:RE:RE:ONCY May 09, 2024 Earnings CallTranscript
Repost: On the topic of our upcoming Type C meeting, as Matt indicated, defining the registrational path for pela in breast cancer is a major goal for Oncolytics in 2024." "
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 02, 2024 11:34pm
RE:RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC
During hypoxic conditions, cells undergo critical adaptive responses that include the up-regulation of hypoxia-inducible proteins (HIFs) and the induction of the unfolded protein response (UPR). ONCY&
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 02, 2024 11:28pm
RE:SABC 2024 - Irene Study Results - Pelareorep in TNBC
T cell exhaustion contributes to therapeutic resistance of TNBC to PD-1/PD-L1 inhibitors. Continuous exposure of T cells to tumor antigens and suppressive cytokines (IL-10, TGF-β) leads to T cell
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Nov 02, 2024 11:23pm
SABC 2024 - Irene Study Results - Pelareorep in TNBC
Poster Session 1 12:30 – 2:00 p.m. Wednesday, December 11 P1-09-19: IRENE study: Phase 2 study of oncolytic virus pelareorep and PD-1 inhibitor retifanlimab in metastatic triple negative breast
...more
(5318)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 01, 2024 2:52pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy
November 01, 2024 - Stephen Schoenberger of the La Jolla Institute for Immunology, described that cancer "vaccines" can activate two different classes of T-cells — “CD8” cells
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden